Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating income | — | -$2.91M | -$7.68M | — | — |
| Net income | — | -$668K | -$7.29M | — | -$19.9M |
| EPS (diluted) | — | — | -$1,248.64 | — | — |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | — | -$1.09M | -$1.52M | — | -$16.1M |
| Share buybacks | — | $139M | $33.5M | — | — |
| Dividends paid | — | — | — | — | $127K |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.10M | $42.1M | $1.60M | $3.33M | $1.66M |
| Total assets | $180M | $42.4M | $5.13M | $6.21M | $3.64M |
| Total liabilities | $9.25M | $39.9M | $5.08M | $8.10M | $9.09M |
| Shareholders' equity | -$7.67M | -$11.0M | -$42.1M | -$2.35M | -$5.45M |
| Retained earnings | — | -$11.0M | -$43.1M | -$70.9M | -$90.8M |
| Shares (wtd avg diluted) | — | — | 5.84B | — | — |
Every figure is extracted from CERO THERAPEUTICS HOLDINGS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.